Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 266

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 266
---
, 2025 or       
 consummation of an IPO.                                                                         |

The Company estimates the fair value
of the 2020 Notes using the Probability-Weighted Expected Return Method (PWERM). For years ended December 31, 2024 and 2023, the Company
recorded an income/ (expense) of $3,483 and $(2,019) for the revaluation of such 2020 Notes, within financial expense, net in the statements
of comprehensive loss.

A summary of significant unobservable
inputs (Level 3 inputs) used in measuring the fair value of 2020 Notes outstanding are as follows:

|                  |     |   | December 31, 
         2024 |   |     |   | December 31, 
         2023 |   |
|:-----------------|:----|:--|-------------:|:--|:----|:--|-------------:|:--|
| Principal amount |     | $ |        1,350 |   |     | $ |          900 |   |
| Discount rate    |     |   |           30 | % |     |   |         30.0 | % |
| Term (years)     |     |   |         0.40 |   |     |   |         0.25 |   |
| Fair value       |     | $ |        4,372 |   |     | $ |        7,405 |   |

<div align='center'>F-17</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 6:- | CONVERTIBLE NOTES (Cont.) |

The Company has performed a sensitivity
analysis of the 2020 Notes which are classified as level 3 financial instruments in the fair value hierarchy. The Company recalculated
the fair value of the 2020 Notes by applying a +/- 5.0% changes to the discount rate used in PWERM.

As of December 31, 2024, a 5.0% decrease
in discount rate would increase the fair value of the 2020 Notes to $4,444; a 5.0% increase in discount rate would decrease the fair
value of the 2020 Notes to $4,305.

c. On March 11, 2023, the Company
converted the 2021